{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:08:05Z","timestamp":1774969685050,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    We previously demonstrated that phosphatidylserine liposomes (PS-L) reduce inflammation and enhance intracellular killing of\n                    <jats:italic>Mycobacterium abscessus<\/jats:italic>\n                    (Mab) in infected human macrophages, with functional or pharmacologically inhibited cystic fibrosis conductance regulator (CFTR). Here, we evaluated the\n                    <jats:italic>in vitro<\/jats:italic>\n                    therapeutic potential of PS-L in macrophages from people with cystic fibrosis (pwCF), either under therapeutic regimen or not with CFTR modulator therapy Elexacaftor\/Tezacaftor\/Ivacaftor (ETI). Results show that PS-L exerted an anti-inflammatory effect in Mab infected macrophages, reducing TNF-\u03b1 and IL-1\u03b2 production and inducing IL-10 release at early and late time points, respectively. In addition, PS-L significantly increased antimycobacterial activity in macrophages from pwCF either undergoing or not ETI regimen. Importantly, in ETI-ineligible pwCF, PS-L alone still was capable to enhance a significant antimycobacterial response. Finally, PS-L combined with amikacin further enhanced intracellular bacterial clearance compared to single treatments. Altogether, these findings support PS-L as a promising host-directed therapy against Mab infection, particularly for pwCF who cannot benefit from ETI.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1681558","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:44:32Z","timestamp":1769582672000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Phosphatidylserine liposomes for Mycobacterium abscessus infections management in people with cystic fibrosis non-eligible for CFTR modulators"],"prefix":"10.3389","volume":"17","author":[{"given":"Tommaso","family":"Olimpieri","sequence":"first","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Poerio","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Saliu","sequence":"additional","affiliation":[{"name":"Emerging Bacteria Pathogens Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola I.","family":"Lor\u00e8","sequence":"additional","affiliation":[{"name":"Emerging Bacteria Pathogens Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Ciciriello","sequence":"additional","affiliation":[{"name":"Pneumology and Cystic Fibrosis Unit, Bambino Ges\u00f9 Children\u2019s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"Ponsecchi","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Alghisi","sequence":"additional","affiliation":[{"name":"Pneumology and Cystic Fibrosis Unit, Bambino Ges\u00f9 Children\u2019s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela M.","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Emerging Bacteria Pathogens Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco M.","family":"D\u2019Andrea","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Fraziano","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203204","article-title":"Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications","volume":"68","author":"Cohen-Cymberknoh","year":"2013","journal-title":"Thorax"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.cmi.2023.06.026","article-title":"The problem of Mycobacterium abscessus complex: multi-drug resistance, bacteriophage susceptibility and potential healthcare transmission","volume":"29","author":"Dedrick","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.3390\/ijms20235868","article-title":"Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients","volume":"20","author":"Degiacomi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.04.001","article-title":"NTM drug discovery: status, gaps and the way forward","volume":"23","author":"Wu","year":"2018","journal-title":"Drug Discov Today"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1456","article-title":"CFTR regulates phagosome acidification in macrophages and alters bactericidal activity","volume":"8","author":"Di","year":"2006","journal-title":"Nat Cell Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1443719","article-title":"Phosphatidylserine liposomes induce a phagosome acidification-dependent and ROS-mediated intracellular killing of Mycobacterium abscessus in human macrophages","volume":"14","author":"Olimpieri","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"107882","DOI":"10.1016\/j.rmed.2024.107882","article-title":"Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal study","volume":"236","author":"Connett","year":"2025","journal-title":"Respir Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.532225","article-title":"Liposomes loaded with phosphatidylinositol 5-phosphate improve the antimicrobial response to pseudomonas aeruginosa in impaired macrophages from cystic fibrosis patients and limit airway inflammatory response","volume":"11","author":"Poerio","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02546-21","article-title":"Combined host- and pathogen-directed therapy for the control of mycobacterium abscessus infection","volume":"10","author":"Poerio","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B13","doi-asserted-by":"crossref","unstructured":"The distinct fate of smooth and rough Mycobacterium abscessus variants inside macrophages\n          \n          160185\n          \n            \n              Roux\n              AL\n            \n            \n              Viljoen\n              A\n            \n            \n              Bah\n              A\n            \n            \n              Simeone\n              R\n            \n            \n              Bernut\n              A\n            \n            \n              Laencina\n              L\n            \n          \n          10.1098\/rsob.160185\n          27906132\n          Open biol.\n          6\n          2016","DOI":"10.1098\/rsob.160185"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf124","article-title":"Phosphatidylinositol 5-phosphate-loaded apoptotic body-like liposomes for mycobacterium abscessus infection management in patients with cystic fibrosis","volume":"232","author":"Olimpieri","year":"2025","journal-title":"J Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.12.001","article-title":"Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis","volume":"9","author":"Esther","year":"2010","journal-title":"J Cyst Fibros: Off J Eur Cyst Fibros Soc"},{"key":"B16","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"B17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-immunol-042617-053010","article-title":"Apoptosis and clearance of apoptotic cells","volume":"36","author":"Nagata","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200484109","article-title":"Janus-faced liposomes enhance antimicrobial innate immune response in Mycobacterium tuberculosis infection","volume":"109","author":"Greco","year":"2012","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1600-0463.2012.02932.x","article-title":"Phagocytosis and cytokine response to rough and smooth colony variants of Mycobacterium abscessus by human peripheral blood mononuclear cells","volume":"121","author":"J\u00f6nsson","year":"2013","journal-title":"APMIS"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2011.72","article-title":"Mycobacterium abscessus activates the NLRP3 inflammasome via Dectin-1-Syk and p62\/SQSTM1","volume":"90","author":"Lee","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"B21","unstructured":"Trikafta, Highlights of Prescribing Information\n          \n          2024"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1522249","article-title":"Multidrug-resistant klebsiella pneumoniae: Challenges for treatment, prevention and infection control","volume":"16","author":"Bassetti","year":"2018","journal-title":"Expert Rev Anti-Infective Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3390\/ph17091151","article-title":"Multidrug-resistant bacteria in immunocompromised patients","volume":"17","author":"Duhaniuc","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00078-5","article-title":"Host-directed therapies for infectious diseases: Current status, recent progress, and future prospects","volume":"16","author":"Zumla","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in inflammatory disease","volume":"20","author":"Kany","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.4.1162","article-title":"Anti-inflammatory cytokines","volume":"117","author":"Opal","year":"2000","journal-title":"Chest"},{"key":"B27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00155","article-title":"The multirole of liposomes in therapy and prevention of infectious diseases","volume":"9","author":"Nisini","year":"2018","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1600-065X.2007.00546.x","article-title":"Lipid signaling and the modulation of surface charge during phagocytosis","volume":"219","author":"Yeung","year":"2007","journal-title":"Immunol Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nsmb.2570","article-title":"Phosphatidylinositol 4,5-bisphosphate clusters act as molecular beacons for vesicle recruitment","volume":"20","author":"Honigmann","year":"2013","journal-title":"Nat Struct Mol Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2016.07.019","article-title":"Manipulation of host membranes by the bacterial pathogens Listeria, Francisella, Shigella and Yersinia","volume":"60","author":"Pizarro-Cerd\u00e1","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ncb854","article-title":"Elimination of host cell Ptdlns(4, 5)P2 by bacterial SigD promotes membrane fission during invasion by Salmonella","volume":"4","author":"Terebiznik","year":"2002","journal-title":"Nat Cell Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1713195115","article-title":"Identification of genes required for Mycobacterium abscessus growth in vivo with a prominent role of the ESX-4 locus","volume":"115","author":"Laencina","year":"2018","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1331508","article-title":"Exploring antibiotic resistance mechanisms in Mycobacterium abscessus for enhanced therapeutic approaches","volume":"15","author":"Nguyen","year":"2024","journal-title":"Front Microbiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1939-4551-6-18","article-title":"Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy","volume":"6","author":"S\u00e1nchez-Borges","year":"2013","journal-title":"World Allergy Organ J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"10882","DOI":"10.1038\/s41598-017-11012-7","article-title":"Ezrin links CFTR to TLR4 signaling to orchestrate anti-bacterial immune response in macrophages","volume":"7","author":"Di Pietro","year":"2017","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1128\/IAI.05303-11","article-title":"The phosphoinositide-3-kinase\u2013akt signaling pathway is important for staphylococcus aureus internalization by endothelial cells","volume":"79","author":"Oviedo-Boyso","year":"2011","journal-title":"Infect Immun"},{"key":"B39","volume-title":"ECFSPR Annual Report 2022","author":"Zolin","year":"2024"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1681558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:44:33Z","timestamp":1769582673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1681558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1681558"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1681558","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"article-number":"1681558"}}